龍記集團控股有限公司 Lung Kee Group Holdings Limited 2024 年 報 2024 ANNUAL REPORT Lung Kee Group Holdings Limited 龍記集團控股有限公司 年 報 Annual Report 2024 年 報 Lung Kee Group Holdings Limited 龍記集團控股有限公司 目 錄 龍記集團控股有限公司 2024 年報 李達義博士 王克勤先生 何腊梅女士 公司秘書 2 公司資料 3 主席報告書 5 管理層之討論及分析 7 企業管治報告 26 環境、社會及管治報告 43 董事會報告書 52 獨立核數師報告書 57 綜合損益及其他全面收益表 58 綜合財務狀況表 60 綜合權益變動表 61 綜合現金流量表 62 綜合財務報表附註 118 五年財務概要 119 持作投資之物業 120 里程碑 公司資料 執行董事 邵鐵龍先生 （主席） 邵玉龍先生 （董事總經理） 韋龍城先生 丁宗浩先生 邵旭桐先生 邵宇衡先生 獨立非執行董事 韋龍城先生 律師 胡關李羅律師行 香港 中環 康樂廣場1號 怡和大廈 26樓 核數師 德勤‧關黃陳方會 ...

2024 Annual 年 報 2024 Report 年報 ANNUAL REPORT 2024 ai1741919504343_Essex_AR24_covcer_OP_03.pdf 1 14/3/2025 ��10:31 全球 生物再生科技 創先者 BUSINESS REVIEW 億勝科技 再生未來 目錄 2 主席報告 10 業務回顧 21 財務摘要 22 財務回顧 28 董事及高級管理層履歷 32 董事會報告 51 獨立核數師報告 55 綜合損益及其他全面收益表 56 綜合財務狀況表 57 綜合權益變動表 58 綜合現金流量表 60 綜合財務報表附註 114 五年財務概要 115 企業管治報告 128 公司資料 主席報告 2 嚴名熾 主席 主席報告 本集團實現營業額約1,669,800,000港元，較上年度減少3.9%（或約人民幣1,537,800,000元，減少2.0%）。有關 減少乃由於中國監管機構於製藥及醫療行業頒佈的若干嚴厲政策和措施。然而，本集團預期，當該等政策和措 施為人們所熟悉時，隨之而來的不利局面將得到緩解（「不可預見因素」）。 本人謹代表億勝生物科技有限公司（「本公司」，連同其附屬公 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （股份代號︰900） （於香港註冊成立之有限公司） 截 至 二 零 二 五 年 二 月 二 十 八 日 止 年 度 之 全 年 業 績 AEON信 貸 財 務（亞 洲）有 限 公 司（「本 公 司」）董 事 會 欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（「本 集 團」）截 至 二 零 二 五 年 二 月 二 十 八 日 止 年 度 之 經 審 核 綜 合 業 績 連 同 比 較 數 字 如 下： 綜 合 損 益 表 截 至 二 零 二 五 年 二 月 二 十 八 日 止 年 度 | | | | | | | | | | | | | | | | | | | 二 | 零 | 二 | 五 | 年 | 二 | 零 二 四 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 GUANGDONG SYNTRUST GK TESTING AND CERTIFICATION TECH SERVICE CENTER CO., LTD. 廣 東 集 信 國 控 檢 測 認 證 技 術 服 務 中 心 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：8629） 有關2024年度報告 之補充公告 茲提述廣東集信國控檢測認證技術服務中心股份有限公司（「本公司」）於2025年 3月21日刊發的截至2024年12月31日止年度的年度報告（「2024年年報」）。除另有 界定者外，本公告所用詞彙與2024年年報所界定者具有相同涵義。 本公司謹此澄清，截至2024年及2023年12月31日止年度，監事並無以彼等作為 監事的身份從本公司收取任何薪酬。然而，截至2024年及2023年12月31日止年 度，監事就其監事職責以外提 ...

2024 年 報 股份代號：1308 （於開曼群島註冊成立的有限公司） Stock Code: 1308 (Incorporated in the Cayman Islands with limited liability) 2024 ANNUAL REPORT Annual Report 年報 2024 目錄 二零二四年 1 2024 年年報 2 公司基本情況 3 公司資料 5 財務及營運摘要 7 二零二四年重要里程碑 10 主席報告書 13 管理層討論及分析 18 董事及高層管理人員 22 董事會報告 42 企業管治報告 54 獨立核數師報告 59 綜合損益及其他全面收益表 61 綜合財務狀況表 63 綜合權益變動表 65 綜合現金流量表 68 財務報表附註 150 五年財務概要 公司基本情況 海豐國際控股有限公司（「本公司」或「海豐國際」或「我們」）是一家亞洲區領先的航運物流集團公司 ，提供綜合運輸及物流 解決方案。於二零二四年十二月三十一日，我們按運力計在全球集裝箱航運企業中排名第15。我們專注於服務亞洲區貿 易市場，根據Drewry Maritime Services (Asia) Pte Ltd（ ...

泸州银行股份有限公司* Luzhou Bank Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 股份代號：1983 (A joint stock company incorporated in the People's Republic of China with limited liability) Stock Code: 1983 一、 公司概況 * Luzhou Bank Co., Ltd. is not an authorised institution within the meaning of the Banking Ordinance (Chapter 155 of the Laws of Hong Kong), not subject to the supervision of the Hong Kong Monetary Authority, and not authorised to carry on banking/deposit-taking business in Hong Kong. 目錄 | 公司簡介 | 2 | | --- | --- | | 會計數據及財務指 ...

Financial Performance - Revenue decreased by 6.8% to RMB 7,469.0 million, compared to RMB 8,013.3 million in the previous year; pharmaceutical sales revenue dropped by 9.0% to RMB 8,621.6 million from RMB 9,472.2 million[8]. - Gross profit declined by 11.2% to RMB 5,422.2 million, down from RMB 6,109.2 million; if calculated based on pharmaceutical sales revenue, gross profit decreased by 10.7% to RMB 5,405.4 million from RMB 6,053.7 million[8]. - Annual profit fell by 32.3% to RMB 1,613.1 million, compared to RMB 2,384.4 million in the previous year; normalized annual profit decreased by 36.7% to RMB 1,713.7 million from RMB 2,709.3 million[8]. - Basic earnings per share dropped by 31.9% to RMB 0.6673, down from RMB 0.9792[8]. - The annual profit was RMB 1,613.1 million, down 32.3% from RMB 2,384.4 million in 2023; excluding asset impairment losses, the profit decreased by 36.7% to RMB 1,713.7 million[35]. - The company’s revenue decreased by 6.8% to RMB 7,469.0 million, down from RMB 8,013.3 million in the same period last year[94]. - Pharmaceutical sales revenue fell by 9.0% to RMB 8,621.6 million, compared to RMB 9,472.2 million last year, primarily due to a decline of RMB 1,086.9 million (28.8%) from three drugs affected by national procurement policies[94]. - Gross profit decreased by 11.2% to RMB 5,422.2 million, with a gross margin of 72.6%, down from 76.2% year-on-year[95]. Research and Development - The company launched 1 new drug and received approval for 1 new indication, with 2 new drug applications submitted and 3 new innovative drug collaborations initiated[9]. - The company has over 10 clinical trials progressing smoothly[13]. - The company has completed Phase II clinical trials for the Y-3 injection, a new brain cell protector for stroke treatment, and is progressing steadily towards Phase III clinical trials in China[16]. - The VEGFA+ANG2 bispecific antibody for neovascular age-related macular degeneration (nAMD) has completed Phase I clinical trials in China, with the first subject dosed in Phase II trials[16]. - The high-selectivity TYK2 inhibitor CMS-D001 tablet for psoriasis and atopic dermatitis has received clinical trial approval in China and is advancing through Phase I trials[16]. - The GnRH receptor antagonist CMS-D002 capsule for moderate to severe pain associated with endometriosis has also received clinical trial approval in China and is progressing through Phase I trials[16]. - The GLP-1R/GCGR dual agonist CMS-D005 injection for obesity/overweight is in preparation for Phase I clinical trials after receiving approval in November 2024, with future development planned for metabolic-related diseases[16]. - The company has secured exclusive rights for the selective oral JAK1 inhibitor povorcitinib for various diseases in multiple regions, including mainland China and Southeast Asia, through a collaboration with Incyte[16]. - The company has obtained exclusive commercialization rights for the URAT1 inhibitor ABP-671 for gout and hyperuricemia in mainland China, Hong Kong, and Macau through a partnership with Hangzhou New Element Pharmaceutical Co., Ltd.[16]. - The company has entered into a collaboration with Alpha Cognition Inc. for the exclusive rights to develop and commercialize a modified new drug for mild to moderate Alzheimer's disease symptoms in Asia, Australia, and New Zealand[16]. - The company has expanded its innovative product pipeline to approximately 40 products, covering conditions such as gout, Alzheimer's disease, vitiligo, atopic dermatitis, and asthma[22]. - The company has committed to increasing investment in the research and development of innovative drugs and rare disease medications[29]. - The company is advancing approximately ten clinical trials focused on registration-based randomized controlled trials (RCTs) to ensure continuous innovation[39]. - The company has about twenty self-developed projects progressing steadily, with four innovative drugs entering the clinical development stage in China[39]. Market Expansion and Strategy - The company is focusing on the Southeast Asian market for international expansion, leveraging its successful commercialization experience in China[26]. - The company has established a local operational network in Southeast Asia, centered around its Singapore headquarters, to address regional pharmaceutical needs[26]. - The company is actively enhancing its international supply chain and production capabilities, having invested in a new production facility in Singapore that has received FDA GMP certification[28]. - The company aims to develop into a leading innovative pharmaceutical enterprise in China, focusing on skin health and ophthalmology[26]. - The company is actively pursuing market expansion and strategic collaborations to enhance its product offerings and therapeutic options[57]. - The ongoing clinical trials and collaborations are expected to strengthen the company's position in the biopharmaceutical market and drive future revenue growth[57]. - The company is considering strategic acquisitions to enhance its market position, targeting companies with a combined revenue of $200 million[134]. - The company is focusing on a patient-centered operational philosophy while enhancing its commercialization system for comprehensive coverage[36]. - The company is implementing refined academic promotion strategies and leveraging digital operations to enhance market penetration in key therapeutic areas[62]. Product Development and Commercialization - The company has successfully launched five innovative products in China, covering six indications, with four of them included in the national medical insurance catalog[38]. - The innovative drug Lefran, approved in June 2024, significantly improved the detection rate of non-polyp colorectal lesions during colonoscopy[40]. - Methotrexate injection, approved in March 2023, is the first pre-filled MTX injection for treating psoriasis and rheumatoid arthritis in China, with its RA indication approved in July 2024[42]. - The company’s product Vifor, the first iron-based non-calcium phosphate binder in China, was approved in February 2023 and has shown a 95% success rate in achieving target serum phosphorus levels[44][45]. - The company has launched a unique recombinant human brain natriuretic peptide (rhBNP) for acute decompensated heart failure, which is the only product of its kind approved by the NMPA in China[64]. - The company is actively expanding its presence in the outpatient market, improving coverage and service quality through training programs for retail pharmacies[63]. - The company is developing new products targeting various conditions, including psoriasis, asthma, and non-alcoholic fatty liver disease, with ongoing clinical trials[61]. - The company has established a commercial system focused on unmet clinical needs, enhancing its specialized business and achieving extensive coverage in both hospital and retail channels[62]. - The company has five innovative drugs that have entered the commercialization stage, supported by a dedicated customer value team to analyze market opportunities and update promotion strategies dynamically[62]. Financial Management and Governance - Cash generated from operating activities was RMB 1,268.5 million, a decrease of 49.3% from RMB 2,502.9 million in the previous year, mainly due to reduced operating profit and increased working capital[114]. - Cash used in investing activities increased by 39.1% to RMB 615.1 million, compared to RMB 442.3 million last year, primarily due to increased spending on product rights[115]. - The group had bank borrowings of RMB 831.3 million as of December 31, 2024, down from RMB 1,269.7 million the previous year, with a debt-to-asset ratio of 4.6%, a decrease of 2.6 percentage points from 7.2%[120]. - The group paid dividends of RMB 364.2 million for the 2024 interim and RMB 192.0 million for the 2023 final, compared to RMB 768.5 million and RMB 591.9 million in the previous year[126]. - The company reported a distributable reserve of RMB 2,694.2 million as of December 31, 2024[145]. - The board proposed a final dividend of RMB 0.1174 per share for the year ending December 31, 2024[148]. - The company has adopted a dividend policy without a preset dividend payout ratio, allowing for flexibility based on various financial and operational factors[149]. - The company has confirmed the independence of all independent non-executive directors as per the listing rules[155]. - The company has established a robust quality management system to comply with GMP and GSP standards, ensuring ongoing regulatory supervision[195]. - The company has not obtained product liability insurance in China, which may expose it to significant costs and damage to customer relationships in case of claims[196]. - The company maintains good relationships with employees, customers, and suppliers, focusing on fair compensation and effective communication[189][190]. Challenges and Risks - The company faced challenges with three original drugs in national procurement, which negatively impacted its performance during the reporting period[35]. - The Chinese healthcare system is undergoing significant reforms, with frequent changes in laws and regulations affecting the healthcare, medical, and pharmaceutical industries, posing risks to the company's operations if strategies are not optimized accordingly[197]. - The company must participate in government-led bidding processes annually or every few years, with failure to win bids potentially impacting product sales in specific provinces[198]. - The successful development, regulatory approval, and commercialization of innovative patented products are influenced by various factors, including resource availability and the uncertainty of approval processes, which could adversely affect the company's future growth if unsuccessful[199]. - There are potential unknown risks and uncertainties that may not be significant now but could become major in the future, impacting the company's operations[200].

二零二四年 獨立財務報表 二零二四年獨立財務報表 Prada店舖 達拉斯NorthPark Center | 1 | | --- | | 公司資料 | | 2 | | 財務回顧 | | 3 | | 企業管治 | | 4 | | 財務報表 | | 5 | | 財務報表附註 | | 6 | | 獨立核數師報告 | | 7 | | 法定核數師委員會報告 | 3 公司資料 第1章 普拉達股份有限公司－公司資料 | 註冊辦事處 | Via A. Fogazzaro, 28 – 20135 Milan, Italy | | --- | --- | | 總辦事處 | Via A. Fogazzaro, 28 – 20135 Milan, Italy | | 根據香港公司條例第16部 | 中國香港特別行政區鰂魚涌 | | 在香港註冊的營業地點 | 英皇道979號太古坊一座8樓 | | 公司網站 | www.pradagroup.com | | 香港聯交所股份代號 | 1913 | | 股本 | 255,882,400歐元 | | | （即2,558,824,000股每股0.10歐元的股份） | | 董事會 | Patrizi ...

Prada店舖 米蘭 埃瑪努埃爾二世拱廊 二零二四年 年 報 值得一提的成就不止於此。Luna Rossa參加第37屆美洲杯帆船 賽， 在女子及青年隊賽事中勇奪冠軍。 此 外，Prada與Axiom Space合作設計新款美國太空總署(NASA)宇航服。 二零二四年，Prada集團再接再厲，在地緣政治動盪成為新常態的 全球背景下，繼續取得優異成績。 儘管行業形勢嚴峻，我們仍然取得優於市場表現的增長，盈利能力 有所提升，進一步印證了我們的策略與執行力。 創此佳績，彰顯了我們品牌的實力，同時亦有賴於我們對質量與創 新的不懈追求，以及通過Prada集團學院不斷豐富並傳承予年輕一 代的工業技術。 我們的製造平台扎根於垂直整合以及與供應商及合作夥伴的長期關 係，從而繼續在追求品質、靈活及高效且不斷演變的產業中脫穎而 出。 創新思維和解讀當代精神的能力作為進一步的獨特元素，培育了我 們產品及策略願景所體現的創意活力。 與文化緊密聯結和拓寬邊界的願景賦予了本集團不竭的精神動力。 舉例而言，坐落於上海市中心、始建於一九一八年的歷史名邸－ Prada榮宅，經過修繕及翻新，將我們的美學與非凡的中華文化遺 產相結合：如今這座建築已 ...

Financial Performance - The company reported original insurance premium income of RMB 538,055 million for 2024, an increase of 4.3% from RMB 515,807 million in 2023[9]. - Insurance service income rose to RMB 485,223 million, reflecting a growth of 6.1% compared to RMB 457,203 million in the previous year[9]. - The company achieved a net profit of RMB 32,161 million, marking a 30.9% increase from RMB 24,566 million in 2023[9]. - Total assets increased by 10.6% to RMB 778,244 million, up from RMB 703,623 million in 2023[11]. - Total liabilities rose by 10.3% to RMB 517,622 million compared to RMB 469,319 million in the previous year[11]. - The company’s total equity increased by 11.2% to RMB 260,622 million from RMB 234,304 million in 2023[11]. - The comprehensive solvency ratio stood at 232.6%, while the core solvency ratio was at 211.0%[15]. - The comprehensive cost ratio stood at 98.8%, with underwriting profit amounting to CNY 5.71 billion and total investment income reaching CNY 34.94 billion, resulting in a net profit of CNY 32.16 billion and a return on equity of 13.0%[21]. - Total investment income amounted to RMB 34.94 billion, with a net profit of RMB 32.16 billion, marking a historical high and a net asset return rate of 13.0%, up 2.2 percentage points year-on-year[27]. - The company's pre-tax profit for 2024 was RMB 38.02 billion, an increase of RMB 9.98 billion (or 35.6%) compared to 2023[61]. - Net profit for 2024 increased to RMB 32.16 billion, up RMB 7.60 billion (or 30.9%) from RMB 24.57 billion in 2023[63]. - The net cash inflow from operating activities was RMB 36.46 billion, a year-on-year increase of RMB 15.92 billion (or 77.5%) in 2024[64]. Dividends and Shareholder Returns - The company plans to distribute a final dividend of RMB 0.332 per share, including an interim dividend of RMB 0.54 per share[15]. - The company distributed an interim dividend of CNY 0.208 per share and proposed a final dividend of CNY 0.332 per share to shareholders[21]. - The company plans to distribute a total dividend of CNY 0.54 per share for the year 2024, with an interim dividend of CNY 0.208 per share already distributed[79]. - The company plans to distribute a final dividend of CNY 0.332 per share for the year ending December 31, 2024, totaling approximately CNY 73.85 billion[131]. Market Position and Growth - The company aims to enhance its market position and continue to innovate in insurance services, contributing to the modernization of China's financial sector[20]. - The company achieved a total original insurance premium income of CNY 538.06 billion in 2024, representing a year-on-year growth of 4.3% and maintaining a market share of 31.8% in the property insurance sector[21][26]. - The company aims to enhance its international market position while consolidating its domestic market leadership, focusing on technological insurance development and green insurance initiatives[24]. - The company processed over 180 million claims throughout the year, demonstrating its commitment to disaster relief and claims service[23]. - The company expanded its market presence by establishing the first comprehensive catastrophe insurance in Hebei and creating a "carbon-neutral" insurance outlet in Xiamen[22]. - The company is considering strategic acquisitions to enhance its service offerings, with potential targets identified in the insurance sector[89]. Innovation and Product Development - The company launched several innovative insurance products, including the "PICC China Earthquake Catastrophe Model" and "Cybersecurity Insurance Risk Pricing Model," enhancing its service offerings[23]. - The company aims to enhance its core competitiveness by innovating business models, particularly in the new energy vehicle insurance sector[83]. - The company will continue to leverage technology, including big data and artificial intelligence, to drive innovation in its business models[83]. - New product launches are expected to contribute an additional 5 billion RMB in revenue over the next fiscal year[92]. Risk Management and Compliance - The company is committed to enhancing risk management capabilities in response to increasing external complexities and climate change risks, focusing on early identification and proactive measures[123]. - The company will focus on risk prevention and management, establishing a comprehensive risk management system to enhance governance and compliance[84]. - The company emphasizes compliance with laws and regulations, maintaining a good overall compliance status in its management activities for 2024[128]. - The company is committed to upholding the principles of diligence and integrity in its operations, as stated by the supervisory board[199]. - In 2024, the company will strengthen internal controls and risk management capabilities as per the Insurance Law of the People's Republic of China[200]. Investment Strategy - The company continues to optimize its investment asset portfolio while adhering to a long-term and stable investment philosophy[54]. - The company intends to invest in high-dividend stocks while maintaining a cautious approach to credit quality and non-standard financial products[84]. - The company has a maximum annual limit of RMB 8,500 million for purchasing debt investment products involving related parties, with actual purchases totaling RMB 3,780 million this year[168]. - The company has a maximum annual limit of RMB 8,500 million for purchasing equity investment products involving related parties, with actual purchases totaling RMB 7,350 million this year[168]. Corporate Governance - The company maintained a strong commitment to corporate governance, with all board members rated as "competent" in their annual performance evaluations[199]. - The supervisory board emphasized the importance of compliance and risk management, regularly reviewing reports from various departments[197]. - The company is committed to enhancing corporate governance in accordance with relevant laws and regulations, including the Company Law and Listing Rules[200]. - The audit committee reviewed the audited performance of the company and its subsidiaries for the year[188]. Social Responsibility and Sustainability - The company is committed to developing green insurance products and promoting ESG practices to support comprehensive green transformation in the economy[82]. - The company has implemented measures to reduce resource consumption, including promoting paperless operations and energy-saving initiatives[127]. - The company has not faced any administrative penalties related to environmental issues in 2024[126]. - The company and its subsidiaries made charitable donations totaling 47 million yuan, with 27 million yuan allocated for public welfare donations[140].